8-K Announcements
6Material company update
Mar 11, 2026·SEC
Material company update
Feb 25, 2026·SEC
Material company update
Jan 2, 2026·SEC
Ironwood Pharmaceuticals, Inc.(IRWD)Earnings, Financials & Key Ratios
IRWD•NASDAQ
$4.83
$788M mkt cap·32.2× P/E·Price updated May 6, 2026
AboutIronwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Show more
- Revenue$296M-15.7%
- EBITDA$121M+26.8%
- Net Income$24M+2629.2%
- EPS (Diluted)0.15+2627.3%
- Gross Margin99.36%+1.5%
- EBITDA Margin40.74%+50.5%
- Operating Margin40.1%+51.3%
- Net Margin8.11%+3138.7%
- ROIC53.97%+88.0%
- Interest Coverage3.14+8.3%
IRWD Key Insights
Ironwood Pharmaceuticals, Inc. (IRWD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓FCF machine: 42.9% free cash flow margin
- ✓Momentum leader: RS Rating 96 (top 4%)
- ✓High quality earnings: Operating CF exceeds net income
✗Weaknesses
- ✗Profits declining 25.7% over 5 years
- ✗Sales declining 5.3% over 5 years
- ✗Shares diluted 11.0% in last year
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
IRWD Price & Volume
Ironwood Pharmaceuticals, Inc. (IRWD) stock price & volume — 10-year historical chart
Loading chart...
IRWD Growth Metrics
Ironwood Pharmaceuticals, Inc. (IRWD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years7.07%
5 Years-5.33%
3 Years-10.32%
TTM-15.72%
Profit CAGR
10 Years-
5 Years-25.72%
3 Years-48.42%
TTM2629.2%
EPS CAGR
10 Years-
5 Years-25.65%
3 Years-46.14%
TTM2394.12%
Return on Capital
10 Years-1.74%
5 Years-1.12%
3 Years-20.42%
Last Year50.89%
IRWD Recent Earnings
Ironwood Pharmaceuticals, Inc. (IRWD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 7/12 qtrs (58%)
Q1 2026Latest
Feb 25, 2026EPS
$0.01
Est $0.02
-150.0%
Revenue
$48M
Est $51M
-6.3%
Q4 2025
Nov 10, 2025EPS
$0.24
Est $0.09
+166.7%
Revenue
$122M
Est $51M
+139.6%
Q3 2025
Aug 7, 2025EPS
$0.14
Est $0.02
+800.0%
Revenue
$85M
Est $78M
+9.5%
Q2 2025
May 7, 2025EPS
$0.14
Est $0.05
-180.0%
Revenue
$41M
Est $71M
-42.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 25, 2026 | $0.01vs $0.02-150.0% | $48Mvs $51M-6.3% |
| Q4 2025 | Nov 10, 2025 | $0.24vs $0.09+166.7% | $122Mvs $51M+139.6% |
| Q3 2025 | Aug 7, 2025 | $0.14vs $0.02+800.0% | $85Mvs $78M+9.5% |
| Q2 2025 | May 7, 2025 | $0.14vs $0.05-180.0% | $41Mvs $71M-42.1% |
Based on last 12 quarters of dataView full earnings history →
IRWD Peer Comparison
Ironwood Pharmaceuticals, Inc. (IRWD) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PTGX | 6.63B | 103.97 | -50.72 | -89.41% | -6.48% | -17.76% | 0.02 | |
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 | |
 CPIX | 65.36M | 4.37 | -23 | 17.57% | -17.6% | -29.73% | 0.41 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 | |
 SHPH | 4.36M | 0.78 | -0.00 | -476.1% | 1.65 | |||
 VNDA | 439.76M | 7.44 | -1.99 | 8.72% | -102.02% | -49.24% | 0.04 | |
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare IRWD vs Peers
Ironwood Pharmaceuticals, Inc. (IRWD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IRWD Income Statement
Ironwood Pharmaceuticals, Inc. (IRWD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 298.28M | 346.64M | 428.41M | 389.52M | 413.75M | 410.6M | 442.74M | 351.41M | 296.15M |
| Revenue Growth % | 8.88% | 16.21% | 23.59% | -9.08% | 6.22% | -0.76% | 7.83% | -20.63% | -15.72% |
| Cost of Goods Sold | 19.41M | 32.75M | 135.39M | 3.14M | 70.41M | 1.42M | 6.15M | 7.55M | 1.88M |
| COGS % of Revenue | 6.51% | 9.45% | 31.6% | 0.81% | 17.02% | 0.35% | 1.39% | 2.15% | 0.64% |
| Gross Profit | 278.87M▲ 0% | 313.89M▲ 12.6% | 293.02M▼ 6.6% | 386.39M▲ 31.9% | 343.35M▼ 11.1% | 409.18M▲ 19.2% | 436.59M▲ 6.7% | 343.86M▼ 21.2% | 294.27M▼ 14.4% |
| Gross Margin % | 93.49% | 90.55% | 68.4% | 99.19% | 82.98% | 99.65% | 98.61% | 97.85% | 99.36% |
| Gross Profit Growth % | 2.49% | 12.56% | -6.65% | 31.86% | -11.14% | 19.17% | 6.7% | -21.24% | -14.42% |
| Operating Expenses | 387.56M | 415.9M | 172.9M | 243.45M | 111.09M | 158.84M | 1.38B | 250.73M | 175.51M |
| OpEx % of Revenue | 129.94% | 119.98% | 40.36% | 62.5% | 26.85% | 38.69% | 312.15% | 71.35% | 59.26% |
| Selling, General & Admin | 233.12M | 241.29M | 0 | 140M | 0 | 115.99M | 0 | 0 | 82.26M |
| SG&A % of Revenue | 78.16% | 69.61% | - | 35.94% | - | 28.25% | - | - | 27.77% |
| Research & Development | 148.23M | 166.5M | 122.24M | 88.06M | 70.41M | 44.27M | 116.08M | 111.42M | 95.14M |
| R&D % of Revenue | 49.69% | 48.03% | 28.53% | 22.61% | 17.02% | 10.78% | 26.22% | 31.71% | 32.12% |
| Other Operating Expenses | 6.21M | 8.11M | 50.66M | 15.38M | 40.68M | -1.42M | 1.27B | 139.31M | -1.88M |
| Operating Income | -77.39M▲ 0% | -238.89M▼ 208.7% | 120.12M▲ 150.3% | 142.94M▲ 19.0% | 232.26M▲ 62.5% | 250.34M▲ 7.8% | -945.43M▼ 477.7% | 93.12M▲ 109.8% | 118.76M▲ 27.5% |
| Operating Margin % | -25.94% | -68.92% | 28.04% | 36.7% | 56.13% | 60.97% | -213.54% | 26.5% | 40.1% |
| Operating Income Growth % | -49.19% | -208.71% | 150.28% | 18.99% | 62.49% | 7.78% | -477.66% | 109.85% | 27.53% |
| EBITDA | -62.77M | -226.92M | 125.7M | 146.5M | 233.78M | 251.75M | -943.86M | 95.14M | 120.64M |
| EBITDA Margin % | -21.04% | -65.46% | 29.34% | 37.61% | 56.5% | 61.31% | -213.19% | 27.07% | 40.74% |
| EBITDA Growth % | -54.56% | -261.53% | 155.39% | 16.55% | 59.57% | 7.69% | -474.91% | 110.08% | 26.81% |
| D&A (Non-Cash Add-back) | 14.62M | 11.97M | 5.58M | 3.56M | 1.52M | 1.42M | 1.57M | 2.01M | 1.88M |
| EBIT | -18.55M | -156.42M | 122.97M | 138.34M | 232.22M | 260.02M | 195.84M | 95.72M | 102.77M |
| Net Interest Income | -34.26M | -34.73M | -33.74M | -27.97M | -30.42M | 1.9M | -2.66M | -28.57M | -28.67M |
| Interest Income | 2.11M | 2.99M | 2.86M | 1.5M | 726K | 9.5M | 18.97M | 4.47M | 4.08M |
| Interest Expense | 36.37M | 37.72M | 36.6M | 29.48M | 31.15M | 7.6M | 21.63M | 33.03M | 32.75M |
| Other Income/Expense | -71.16M | -43.48M | -61.18M | -34.08M | -31.6M | 2.08M | -2.64M | -27.93M | -48.73M |
| Pretax Income | -116.94M▲ 0% | -282.37M▼ 141.5% | 58.94M▲ 120.9% | 108.86M▲ 84.7% | 200.66M▲ 84.3% | 252.42M▲ 25.8% | -948.07M▼ 475.6% | 65.2M▲ 106.9% | 70.03M▲ 7.4% |
| Pretax Margin % | -39.2% | -81.46% | 13.76% | 27.95% | 48.5% | 61.48% | -214.14% | 18.55% | 23.64% |
| Income Tax | 34.26M | -5.75M | 0 | 2.69M | -327.79M | 77.36M | 83.49M | 64.32M | 46.01M |
| Effective Tax Rate % | -29.3% | 2.04% | 0% | 2.47% | -163.36% | 30.65% | -8.81% | 98.65% | 65.7% |
| Net Income | -116.94M▲ 0% | -282.37M▼ 141.5% | 21.5M▲ 107.6% | 106.18M▲ 393.7% | 528.45M▲ 397.7% | 175.06M▼ 66.9% | -1B▼ 672.5% | 880K▲ 100.1% | 24.02M▲ 2629.2% |
| Net Margin % | -39.2% | -81.46% | 5.02% | 27.26% | 127.72% | 42.64% | -226.37% | 0.25% | 8.11% |
| Net Income Growth % | -43.12% | -141.47% | 107.62% | 393.73% | 397.71% | -66.87% | -672.5% | 100.09% | 2629.2% |
| Net Income (Continuing) | -54.91M | -194.15M | 58.94M | 106.18M | 528.45M | 175.06M | -1.03B | 880K | 24.02M |
| Discontinued Operations | 0 | 0 | -37.44M | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.78▲ 0% | -1.85▼ 137.2% | -0.10▲ 94.7% | 0.66▲ 772.1% | 3.21▲ 386.4% | 0.96▼ 70.1% | -6.45▼ 771.9% | 0.01▲ 100.1% | 0.15▲ 2627.3% |
| EPS Growth % | -39.29% | -137.18% | 94.69% | 772.1% | 386.36% | -70.09% | -771.88% | 100.09% | - |
| EPS (Basic) | -0.79 | -1.85 | -0.10 | 0.67 | 3.26 | 1.13 | -6.45 | 0.01 | 0.15 |
| Diluted Shares Outstanding | 148.99M | 152.63M | 156.02M | 160.66M | 164.42M | 186.31M | 155.44M | 160.08M | 177.76M |
| Basic Shares Outstanding | 148.42M | 152.63M | 156.02M | 159.43M | 162.25M | 154.37M | 155.44M | 159.08M | 162.22M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IRWD Balance Sheet
Ironwood Pharmaceuticals, Inc. (IRWD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 311.6M | 266.44M | 306.85M | 495.84M | 745.23M | 780.63M | 233.29M | 182.37M | 274.18M |
| Cash & Short-Term Investments | 221.42M | 173.17M | 177.02M | 364.3M | 620.13M | 656.2M | 92.15M | 88.56M | 215.46M |
| Cash Only | 125.74M | 173.17M | 177.02M | 364.3M | 620.13M | 656.2M | 92.15M | 88.56M | 215.46M |
| Short-Term Investments | 95.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 82.16M | 80.95M | 117.25M | 122.35M | 114.04M | 115.46M | 129.12M | 81.89M | 46.74M |
| Days Sales Outstanding | 100.54 | 85.24 | 99.89 | 114.65 | 100.6 | 102.64 | 106.45 | 85.05 | 57.61 |
| Inventory | 735K | 0 | 648K | 0 | 0 | 1.25M | 0 | 0 | 0 |
| Days Inventory Outstanding | 13.82 | - | 1.75 | - | - | 321.76 | - | - | - |
| Other Current Assets | 0 | 2.1M | 1.25M | 9.19M | 2.37M | 0 | 0 | 11.92M | 11.98M |
| Total Non-Current Assets | 294.08M | 65.61M | 95.9M | 63.4M | 381.7M | 319.89M | 237.78M | 168.54M | 122.72M |
| Property, Plant & Equipment | 17.27M | 17.27M | 30.17M | 25.5M | 22.93M | 20.31M | 18.17M | 15.52M | 12.75M |
| Fixed Asset Turnover | 17.27x | 20.07x | 14.20x | 15.27x | 18.05x | 20.22x | 24.36x | 22.64x | 23.23x |
| Goodwill | 785K | 785K | 785K | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 159.91M | 0 | 0 | 0 | 0 | 0 | 3.68M | 2.86M | 2.04M |
| Long-Term Investments | 115.24M | 47.45M | 0 | 36.95M | 0 | 15.07M | 0 | 0 | 0 |
| Other Non-Current Assets | 116.11M | 47.56M | 64.94M | 943K | 358.78M | 847K | 3.61M | 5.92M | 4.5M |
| Total Assets | 605.67M▲ 0% | 332.05M▼ 45.2% | 402.75M▲ 21.3% | 559.24M▲ 38.9% | 1.13B▲ 101.5% | 1.1B▼ 2.3% | 471.07M▼ 57.2% | 350.91M▼ 25.5% | 396.9M▲ 13.1% |
| Asset Turnover | 0.49x | 1.04x | 1.06x | 0.70x | 0.37x | 0.37x | 0.94x | 1.00x | 0.75x |
| Asset Growth % | -14.67% | -45.18% | 21.29% | 38.86% | 101.51% | -2.34% | -57.2% | -25.51% | 13.11% |
| Total Current Liabilities | 66.03M | 119.52M | 40.93M | 32.17M | 161.7M | 25.52M | 276.1M | 38.85M | 242.22M |
| Accounts Payable | 15.96M | 14.89M | 5.49M | 661K | 935K | 483K | 7.83M | 2.13M | 2.9M |
| Days Payables Outstanding | 300.15 | 165.96 | 14.79 | 76.93 | 4.85 | 124.33 | 464.86 | 102.8 | 562.34 |
| Short-Term Debt | 4.08M | 47.55M | 0 | 3.13M | 116.86M | 0 | 199.56M | 0 | 202.93M |
| Deferred Revenue (Current) | 195K | 252K | 875K | 0 | 0 | 0 | 2.62M | 2.03M | 0 |
| Other Current Liabilities | 23.23M | 42M | 14.89M | 14.97M | 7.49M | 15.88M | 26.13M | 4.98M | 35.46M |
| Current Ratio | 4.72x | 2.23x | 7.50x | 15.41x | 4.61x | 30.58x | 0.84x | 4.69x | 1.13x |
| Quick Ratio | 4.71x | 2.23x | 7.48x | 15.41x | 4.61x | 30.53x | 0.84x | 4.69x | 1.13x |
| Cash Conversion Cycle | -185.79 | - | 86.85 | - | - | 300.07 | - | - | - |
| Total Non-Current Liabilities | 529.8M | 408.9M | 455.07M | 464.43M | 359.32M | 422.62M | 541.27M | 613.4M | 416.52M |
| Long-Term Debt | 396.09M | 366.14M | 407.99M | 430.26M | 337.33M | 396.25M | 498.31M | 583.99M | 385M |
| Capital Lease Obligations | 0 | 158K | 22.08M | 20.32M | 18.48M | 16.6M | 14.54M | 12.3M | 9.87M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 133.71M | 42.6M | 24.99M | 13.85M | 3.5M | 9.77M | 28.41M | 17.11M | 21.65M |
| Total Liabilities | 595.83M | 528.42M | 496M | 496.6M | 521.02M | 448.14M | 817.37M | 652.24M | 658.74M |
| Total Debt | 400.17M | 413.92M | 431.22M | 453.7M | 475.8M | 415.92M | 715.54M | 599.48M | 597.8M |
| Net Debt | 274.43M | 240.75M | 254.2M | 89.4M | -144.33M | -240.29M | 623.38M | 510.92M | 382.35M |
| Debt / Equity | 40.63x | - | - | 7.24x | 0.79x | 0.64x | - | - | - |
| Debt / EBITDA | - | - | 3.43x | 3.10x | 2.04x | 1.65x | - | 6.30x | 4.96x |
| Net Debt / EBITDA | - | - | 2.02x | 0.61x | -0.62x | -0.95x | - | 5.37x | 3.17x |
| Interest Coverage | -0.51x | -4.15x | 3.36x | 4.69x | 7.45x | 34.22x | 9.05x | 2.90x | 3.14x |
| Total Equity | 9.85M▲ 0% | -196.37M▼ 2094.0% | -93.25M▲ 52.5% | 62.64M▲ 167.2% | 605.91M▲ 867.3% | 652.38M▲ 7.7% | -346.3M▼ 153.1% | -301.33M▲ 13.0% | -261.83M▲ 13.1% |
| Equity Growth % | -85.24% | -2094.02% | 52.51% | 167.17% | 867.29% | 7.67% | -153.08% | 12.98% | 13.11% |
| Book Value per Share | 0.07 | -1.29 | -0.60 | 0.39 | 3.69 | 3.50 | -2.23 | -1.88 | -1.47 |
| Total Shareholders' Equity | 9.85M | -196.37M | -93.25M | 62.64M | 605.91M | 652.38M | -346.3M | -301.33M | -261.83M |
| Common Stock | 151K | 154K | 158K | 161K | 162K | 154K | 156K | 160K | 163K |
| Retained Earnings | -1.31B | -1.59B | -1.57B | -1.47B | -937.61M | -696.38M | -1.7B | -1.7B | -1.67B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -79K | 0 | -10.08M | 0 | 0 | 0 | -3.03M | 923K | -1.06M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IRWD Cash Flow Statement
Ironwood Pharmaceuticals, Inc. (IRWD) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -99.56M | -70.88M | 10.72M | 168.84M | 261.89M | 273.76M | 183.43M | 103.55M | 127.04M |
| Operating CF Margin % | -33.38% | -20.45% | 2.5% | 43.34% | 63.3% | 66.67% | 41.43% | 29.47% | 42.9% |
| Operating CF Growth % | -291.47% | 28.81% | 115.13% | 1474.23% | 55.12% | 4.53% | -33% | -43.55% | 22.69% |
| Net Income | -116.94M | -282.37M | 21.5M | 106.18M | 528.45M | 175.06M | -1B | 880K | 24.02M |
| Depreciation & Amortization | 14.62M | 14.22M | 5.58M | 3.56M | 1.5M | 1.42M | 1.57M | 2.01M | 1.88M |
| Stock-Based Compensation | 33.82M | 43.98M | 31.28M | 31.18M | 22.28M | 27.05M | 32.01M | 29.85M | 17.25M |
| Deferred Taxes | 7.53M | 159.11M | 0 | 6.6M | -333.29M | 65.74M | 72.64M | 68.09M | 40.8M |
| Other Non-Cash Items | -16.81M | -13.44M | 52.35M | 22.26M | 25.23M | 1.67M | 1.07B | 1.98M | 3.44M |
| Working Capital Changes | -21.79M | 7.62M | -99.99M | -941K | 17.73M | 2.82M | 11.28M | 739K | 39.65M |
| Change in Receivables | -17.3M | 1.21M | -68.89M | 4.09M | 7.71M | 7.99M | 924K | 47.24M | 35.15M |
| Change in Inventory | 346K | -806K | 0 | 648K | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -6.84M | 8.06M | -32.7M | -7.52M | -2.64M | -8.12M | 12.38M | -20.21M | 6.2M |
| Cash from Investing | 151.46M | 88.87M | -11.14M | -1.84M | -265K | -136K | -1.03B | -142K | -34K |
| Capital Expenditures | -4.21M | -8.62M | -7.19M | -1.84M | -265K | -136K | -273K | -142K | -34K |
| CapEx % of Revenue | 1.41% | 2.49% | 1.68% | 0.47% | 0.06% | 0.03% | 0.06% | 0.04% | 0.01% |
| Acquisitions | 135K | 1.56M | 0 | 0 | 0 | 0 | -1.03B | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 135K | 1.56M | -3.96M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 19.84M | 30.07M | -1.19M | 18.55M | -4.55M | -237.55M | 277.16M | -106.97M | 216K |
| Debt Issued (Net) | 8.76M | -1.82M | 19.43M | 0 | 0 | -120.7M | 300M | -115M | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 18.55M | -24.13M | -126.39M | 6.36M | 11.01M | 216K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | -24.13M | -126.39M | 0 | 0 | 0 |
| Other Financing | 11.08M | 31.9M | -20.61M | 0 | 19.58M | 9.54M | -29.2M | -2.98M | 0 |
| Net Change in Cash | 71.73M▲ 0% | 48.06M▼ 33.0% | -1.6M▼ 103.3% | 185.54M▲ 11667.3% | 257.08M▲ 38.6% | 36.07M▼ 86.0% | -565.78M▼ 1668.4% | -3.6M▲ 99.4% | 126.9M▲ 3629.8% |
| Free Cash Flow | -103.77M▲ 0% | -79.5M▲ 23.4% | 3.54M▲ 104.4% | 166.99M▲ 4622.7% | 261.63M▲ 56.7% | 273.63M▲ 4.6% | 183.15M▼ 33.1% | 103.41M▼ 43.5% | 127.01M▲ 22.8% |
| FCF Margin % | -34.79% | -22.94% | 0.83% | 42.87% | 63.23% | 66.64% | 41.37% | 29.43% | 42.89% |
| FCF Growth % | 19.95% | 23.39% | 104.45% | 4622.68% | 56.67% | 4.59% | -33.06% | -43.54% | 22.83% |
| FCF per Share | -0.70 | -0.52 | 0.02 | 1.04 | 1.59 | 1.47 | 1.18 | 0.65 | 0.71 |
| FCF Conversion (FCF/Net Income) | 0.85x | 0.25x | 0.50x | 1.59x | 0.50x | 1.56x | -0.18x | 117.67x | 5.29x |
| Interest Paid | 0 | 0 | 17.58M | 7.22M | 7.22M | 5.75M | 13.55M | 32.56M | 0 |
| Taxes Paid | 0 | 0 | 0 | 1.85M | 3.45M | 4.62M | 9.95M | 8.41M | 0 |
IRWD Key Ratios
Ironwood Pharmaceuticals, Inc. (IRWD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -100.97% | -305.46% | - | - | 169.5% | 158.09% | 27.83% | -654.88% | - | - |
| Return on Invested Capital (ROIC) | -12.95% | -17.33% | -109.03% | 87.75% | 68.5% | 56.78% | 42.98% | -205.77% | 28.7% | 53.97% |
| Gross Margin | 99.32% | 93.49% | 90.55% | 68.4% | 99.19% | 82.98% | 99.65% | 98.61% | 97.85% | 99.36% |
| Net Margin | -29.83% | -39.2% | -81.46% | 5.02% | 27.26% | 127.72% | 42.64% | -226.37% | 0.25% | 8.11% |
| Debt / Equity | 5.59x | 40.63x | - | - | 7.24x | 0.79x | 0.64x | - | - | - |
| Interest Coverage | -1.09x | -0.51x | -4.15x | 3.36x | 4.69x | 7.45x | 34.22x | 9.05x | 2.90x | 3.14x |
| FCF Conversion | 0.31x | 0.85x | 0.25x | 0.50x | 1.59x | 0.50x | 1.56x | -0.18x | 117.67x | 5.29x |
| Revenue Growth | 83.18% | 8.88% | 16.21% | 23.59% | -9.08% | 6.22% | -0.76% | 7.83% | -20.63% | -15.72% |
IRWD SEC Filings & Documents
Ironwood Pharmaceuticals, Inc. (IRWD) SEC filings — annual & quarterly reports (10-K, 10-Q)
IRWD Frequently Asked Questions
Ironwood Pharmaceuticals, Inc. (IRWD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Ironwood Pharmaceuticals, Inc. (IRWD) reported $296.2M in revenue for fiscal year 2025. This represents a 2730% increase from $10.5M in 2007.
Ironwood Pharmaceuticals, Inc. (IRWD) saw revenue decline by 15.7% over the past year.
Yes, Ironwood Pharmaceuticals, Inc. (IRWD) is profitable, generating $24.0M in net income for fiscal year 2025 (8.1% net margin).
Dividend & Returns
Ironwood Pharmaceuticals, Inc. (IRWD) generated $127.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More IRWD
Ironwood Pharmaceuticals, Inc. (IRWD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates